CANG vs AUTL vs CAAS

For growth investors, Autolus Therapeutics plc (AUTL) is the stronger pick with 496.

0% revenue growth year-over-year, versus -52. 7% for Cango Inc. (CANG). China Automotive Systems, Inc. (CAAS) offers the better valuation at 3. 2x trailing P/E (7. 1x forward), making it the more compelling value choice. Analysts rate Cango Inc. (CANG) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, China Automotive Systems, Inc.

(CAAS) is the cheapest at 3. 2x versus Cango Inc. at 5. 7x.

Over the past 5 years, China Automotive Systems, Inc.

(CAAS) delivered a total return of +23. 3%, compared to -70. 1% for Autolus Therapeutics plc (AUTL). Over 10 years, the gap is even starker: CAAS returned +35. 2% versus AUTL's -93. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), China Automotive Systems, Inc.

(CAAS) is the lower-risk stock at 0. 42β versus Cango Inc. 's 2. 25β — meaning CANG is approximately 442% more volatile than CAAS relative to the S&P 500. On balance sheet safety, Cango Inc. (CANG) carries a lower debt/equity ratio of 4% versus 46% for China Automotive Systems, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Autolus Therapeutics plc (AUTL) is pulling ahead at 496.

0% versus -52. 7% for Cango Inc. (CANG). On earnings-per-share growth, the picture is similar: Cango Inc. grew EPS 960. 0% year-over-year, compared to 27. 5% for Autolus Therapeutics plc. Over a 3-year CAGR, AUTL leads at 88. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Cango Inc.

(CANG) is the more profitable company, earning 37. 3% net margin versus -21. 8% for Autolus Therapeutics plc — meaning it keeps 37. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CANG leads at 22. 2% versus -23. 9% for AUTL. At the gross margin level — before operating expenses — CANG leads at 55. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CANG: 459.

2% to $3. 00.

In this comparison, CAAS (1.

6% yield) pays a dividend. CANG, AUTL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, China Automotive Systems, Inc.

(CAAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 42), 1. 6% yield). Cango Inc. (CANG) carries a higher beta of 2. 25 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CAAS: +35. 2%, CANG: -44. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CANG (Consumer Cyclical) and AUTL (Healthcare) and CAAS (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CANG is a small-cap deep-value stock; AUTL is a small-cap high-growth stock; CAAS is a small-cap high-growth stock. CAAS pays a dividend while CANG, AUTL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.